Belgium : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press/Media

Period27 Oct 2022

Media coverage

1

Media coverage